活性重组蛋白Recombinant Human Erythropoietin EPO Protein　重组蛋白

种属

Human

表达宿主

HEK293 cells

描述

Recombinant Human Erythropoietin/EPO Protein is produced by HEK293 cells expression system. The target protein is expressed with sequence (Ala28-Arg193) of human EPO/MVCD2 (Accession #NP_000790.2) fused with a hFc tag at the C-terminus.

标签

C-hFc

纯度

> 95% by SDS-PAGE.

内毒素

<0.1EU/μg

生物活性

1.Measured by its binding ability in a functional ELISA. Immobilized Human EPOR at 1 μg/mL (100 μL/well) can bind Human EPO with a linear range of 0.24-74.89 ng/mL.
2.Measured in a cell proliferation assay using TF1 human erythroleukemic cells. The ED50 for this effect is 2.37-9.48 ng/mL.

制剂

Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.4.

储存

Store the lyophilized protein at -20°C to -80°C for long term.
After reconstitution, the protein solution is stable at -20°C for 3 months, at 2-8°C for up to 1 week.未开盖的干粉蛋白在 -20°C至-80°C可保存12个月；
复溶之后，蛋白溶液在-20°C及以下可保存3个月，在2-8℃可保存1周。

复溶

Centrifuge the vial before opening. Reconstitute to a concentration of 0.1-0.5 mg/mL in sterile distilled water. Avoid votex or vigorously pipetting the protein. For long term storage, it is recommended to add a carrier protein or stablizer (e.g. 0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose), and aliquot the reconstituted protein solution to minimize free-thaw cycles.收到重组蛋白产品之后请检查蛋白冻干粉末是否贴于瓶底，如果粉末浮起，开盖之前请先低温离心。将蛋白用说明书中指定的缓冲液复溶至0.1-0.5 mg/mL（请注意蛋白复溶浓度不能低于0.1 mg/mL），室温平衡5-10 min保证充分溶解，复溶过程中请不要剧烈涡旋及吹打蛋白溶液。如需长期储存，建议复溶时添加载体蛋白或者稳定剂（如0.1% BSA, 5% HSA, 10% FBS 或者 5% 海藻糖），同时将复溶后的蛋白溶液按照需求进行分装，储存于-20°C至-80°C，随取随用，避免反复冻融。

背景信息

Human Erythropoietin (EPO) is also known as EP, erythropoetin or erthropoyetin, and is a glycoprotein hormone that controls erythropoiesis, or red blood cell production.It has neuroprotective activity against a variety of potential brain injuries and antiapoptotic functions in several tissue types. Erythropoietin is the principal hormone involved in the regulation of erythrocyte differentiation and the maintenance of a physiological level of circulating erythrocyte mass. It is produced by kidney or liver of adult mammals and by liver of fetal or neonatal mammals. Genetic variation in erythropoietin is associated with susceptbility to microvascular complications of diabetes type 2. These are pathological conditions that develop in numerous tissues and organs as a consequence of diabetes mellitus. They include diabetic retinopathy, diabetic nephropathy leading to end-stage renal disease, and diabetic neuropathy. Diabetic retinopathy remains the major cause of new-onset blindness among diabetic adults. It is characterized by vascular permeability and increased tissue ischemia and angiogenesis. It has a longer circulating half-life in vivo. Erythropoietin is being much misused as a performance-enhancing drug in endurance athletes.

基因ID

2056

Swiss Prot

P01588

别名

EPO;EP;MVCD2